STAT Plus: Pharmalittle: Coronavirus spread may hurt pharma’s supply chain; Illinois limits out-of-pocket insulin costs
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
Category: STAT Plus
STAT Plus: ‘The gurus of sperm’: Ohana Biosciences is taking a different approach to fertility
“Ohana” means family in Hawaiian — and the new Cambridge, Mass.-based biotech that took that…
STAT Plus: These 10 startups acquired by Alphabet reveal a health care play centered on surveillance
At a gathering of the world’s business and political titans last week, Google CEO Sundar…
.jpg)
STAT Plus: Another patient charity settles charges it helped drug makers pay Medicare kickbacks
After a contentious, two-year battle with federal authorities, a patient charity called Patient Services agreed…
STAT Plus: What does the latest twist in the Sarepta saga mean for the future of the FDA? We discuss
Earlier this week, the Food and Drug Administration released documents that reveal a schism within…
STAT Plus: Insys founder gets 5½ years in jail for his role in fentanyl prescription scheme
The founder of Insys Therapeutics was sentenced to 5½ years in federal prison Thursday for…
STAT Plus: Pharmalittle: Drug makers spent $120 million lobbying Congress in 2019; more investors are bullish in Biogen’s Alzheimer drug
And so, another working week will soon draw to a close. Not a moment too…
STAT Plus: Former Insys executive who dressed as giant fentanyl bottle gets 26-month sentence
A former high-ranking Insys Therapeutics executive who dressed as a giant fentanyl spray bottle in…
STAT Plus: Many patient groups have deep ties to pharma but fail to disclose backing
Amid ongoing debate over the role the pharmaceutical industry plays in shaping health policy, a…
.jpg)
STAT Plus: Pharmalittle: Most Americans worry about drug prices, not Medicare for All; FDA remains divided over a drug
Top of the morning to you, and a fine one it is. Our short person…
STAT Plus: Civica Rx teams with Blue Cross Blue Shield to widen its alternative market for generics
In its latest bid to rework the marketplace for generic drugs, the Civica Rx nonprofit…
STAT Plus: Former Insys executive sentenced to a year and a day for her role in opioid bribery scheme
A former pharmaceutical executive and one-time stripper was sentenced to a year and a day…
STAT Plus: The FDA continues to struggle with the implications of approving Sarepta’s drugs
New documents released Wednesday lay bare the stark divide within the Food and Drug Administration…
STAT Plus: European Court adviser deals Glaxo a setback in ‘pay-to-delay’ case
In a setback to GlaxoSmithKline (GSK), a legal adviser to the European Court of Justice…
STAT Plus: European court upholds controversial EMA transparency rules for clinical trial data
After months of anticipation, the European Court of Justice has sided with the European Medicines…
STAT Plus: Pharmalittle: Connecticut lawmakers look to cap insulin prices; Glaxo halts Excedrin production
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it…
STAT Plus: Amid a competitor’s struggles, a startup with a fraction of its funding takes on ‘digital pills’
A version of this story appeared in STAT’s Health Tech newsletter. Click here to subscribe….
STAT Plus: Verily’s top health leaders: We’re ‘trying to solve problems that many of us have lived’
SAN FRANCISCO — Andy Conrad, the CEO of Verily, the life sciences unit of search…
STAT Plus: As prescribing for ADHD stimulants rose, so did industry payments to doctors
At the same time that more doctors were prescribing stimulants, a new analysis finds that…
STAT Plus: Pharma is making some effort to fight superbugs, but progress is ‘patchy’
Amid rising concern over a lack of antibiotics, a new analysis finds most drug makers…
STAT Plus: Could a drug for arthritis in dogs also fight cancer in people?
Drugs for diabetes, inflammation, alcoholism — and even for treating arthritis in dogs — can…
STAT Plus: Pharmalittle: Indian drug makers receive most FDA warning letters; most clinical trial results go unreported
Hello, everyone, and nice to see you again. We have finally returned from an extended…
STAT Plus: A Q&A with Gates Foundation CEO Sue Desmond-Hellmann
Sue Desmond-Hellmann has some experience when it comes to health care. She began her career…
STAT Plus: This CEO wants to make telehealth more than ‘an exercise in convenience’
SAN FRANCISCO — The year was 2007. To raucous applause, Apple CEO Steve Jobs proudly…
STAT Plus: How swallowing a star might keep you from missing a dose of medicine
SAN FRANCISCO — Plenty of drug industry executives who take over this city for a…
STAT Plus: Pharmalittle: FTC member favors Medicare negotiation on drug prices; BioMarin weighs pricing world’s most expensive drug
Good morning. Elizabeth Cooney here again, channeling Ed Silverman as another week draws to a…
STAT Plus: ‘We have a tragedy of the commons’: How a VC thinks his new company can lower drug prices
A venture capitalist made some waves early in the J.P. Morgan Healthcare Conference when he…
STAT Plus: Airing frustrations with pharma, a Republican FTC commissioner just endorsed Medicare negotiation
WASHINGTON — A Republican member of the Federal Trade Commission on Thursday expressed support for…
STAT Plus: Lilly exec says ‘there are no villains’ in the high-priced insulin market
Several months ago, Eli Lilly (LLY) launched LisPro, an authorized generic version of its Humalog…
STAT Plus: A venture firm warms to funding neuroscience
Longtime venture capital star Beth Seidenberg and former Amgen R&D chief Sean Harper say they…
STAT Plus: Regeneron’s Yancopoulos is still bitter over Praluent sales. Can Novartis do better?
SAN FRANCISCO — George Yancopoulos, Regeneron Pharma’s top scientist, is still a bit bitter about…
STAT Plus: Startup Spotlight: With a different method for gene therapy, Generation Bio eyes an IPO
Seven years ago, one of Generation Bio’s scientific founders couldn’t convince any top-tier journals to…
STAT Plus: At JPM, a debate on Alzheimer’s disease, some family drama in oncology, and a beaten-down biotech
SAN FRANCISCO — While the early hours of biotech’s biggest annual meeting didn’t bring any…
STAT Plus: Pharmalittle: Roche plans aggressive SMA drug pricing; where are those clinical trial results?
Good morning. Elizabeth Cooney here in Boston while Ed Silverman hobnobs with industry types at…
STAT Plus: Pharmalittle: AstraZeneca fish oil pill flops; boom in biopharma dealmaking predicted for 2020
Good morning. Elizabeth Cooney sitting in for Ed Silverman, who is covering the J.P. Morgan…
STAT Plus: Eyeing more data, Livongo will integrate continuous glucose monitor into diabetes coaching program
SAN FRANCISCO — For companies that monitor and coach patients with chronic disease, there are…
STAT Plus: AstraZeneca fish oil drug fails, leaving Amarin as last drug standing
AstraZeneca (AZN) said Monday that it would stop a large clinical study of a fish-oil-derived…
STAT Plus: Facebook’s new tool promotes preventive health. But the company can’t tell if it’s working
LAS VEGAS — As Facebook’s newest health tool makes its way to your feed, the…
STAT Plus: Supreme Court will review an Arkansas law governing pharmacy benefit managers
In a move with the potential to affect health care costs, the U.S. Supreme Court…
STAT Plus: Apple came to the world’s biggest tech conference for the first time in 28 years. It barely talked about health
Breaking a 28-year hiatus, Apple made an appearance this week at the annual Consumer Electronics…
STAT Plus: Not so fast: 5 reasons to view declining cancer death rates with a dash of skepticism
Not to be a downer at the start of the new year, but might it…
STAT Plus: Pharmalittle: Combining antibiotics may cause resistance; Lilly moves into dermatitis market with $1.1 billion deal
And so, another working week will soon draw to a close. Not a moment too…
STAT Plus: Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline
Eli Lilly said Friday that it will acquire Dermira, a small biotech developing drugs for…
STAT Plus: Blueprint gains approval for its first drug, a treatment for a rare gastrointestinal cancer
Blueprint Medicines won approval Thursday of its first drug, a precision medicine that dramatically shrank…
STAT Plus: Bristol-Myers and Sanofi accuse Hawaii of violating their free speech rights
In an unusual move, two of the world’s biggest drug makers — Bristol-Myers Squibb (BMY)…
STAT Plus: Pharmalittle: More companies recall heartburn tablets; Merck’s Keytruda wins another cancer approval
Top of the morning to you, and a fine one, it is, thanks to clear…
STAT Plus: Pharmalittle: More companies recall heartburn tablets; Merck’s Keytruda wins another cancer approval
Top of the morning to you, and a fine one, it is, thanks to clear…
STAT Plus: Regeneron drug reduces bone growth for patients with ultra-rare skeletal disease
Patients with the ultra-rare disease FOP grow bone where it doesn’t belong, creating a life-threatening…
STAT Plus: Pharmalittle: Execs vow to place patients ahead of profits; conservatives like Republican drug pricing bill
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it…
STAT Plus: A Q&A with FDA’s Amy Abernethy on how the agency is grappling with digital health regulation
LAS VEGAS — The Food and Drug Administration announced this week it will hold a…